comparemela.com

Page 4 - Raquel Cona News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy ; On Track to Report Interim Analysis in Fourth Quarter of 2023- -Plan to. | May 11, 2023

San diegoUnited statesJoyce allaireLinda marbRaquel conaExosome platform technologyCapricor therapeutics incNippon shinyaku co ltdWorld vaccine congressGlobenewswire incCapricor company contactClinical research forumDuchenne muscular dystrophy programExchange commissionLifesci advisorsStrategic communications

Capricor Therapeutics Presents at 2023 Muscular Dystrophy

Late-Breaking Presentation Highlighted Positive18-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients.

United statesLinda marbJoyce allaireCraig mcdonaldRaquel conaExchange commission onMuscular dystrophy associationDepartment of physical medicineCapricor company contactStrategic communicationsCapricor therapeutics incUniversity of californiaLifesci advisorsScientific conferencePrincipal investigatorPhysical medicine

Capricor Therapeutics and Nippon Shinyaku Enter Partnership

-Expands Partnership with Nippon Shinyaku to Japan to Leverage Deep Experience in Drug Development for Rare Diseases and Commercial DMD Franchise- .

United statesLinda marbToru nakaiJoyce allaireRaquel conaNippon shinyaku co ltdLifesci advisorsExchange commission onCorporate communications deptStrategic communicationsCapricor therapeutics incCapricor company contactExpands partnershipNippon shinyakuLeverage deep experienceDrug development

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program

19.01.2023 - -Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular dystrophy- -Webinar to be held on Wednesday, January 25, 2023 at 1:00 p.m. ET- SAN DIEGO, Jan. 19, 2023 .

Joyce allaireRaquel conaLifesci advisorsExchange commission onCapricor therapeutics incStrategic communicationsParent project muscular dystrophyPrivate securities litigation reform actAnnual reportExchange commissionQuarterly reportInvestigational new drugMedia contactInvestor contactSci advisors

Capricor Announces Publication Highlighting New Advances

-StealthX™ Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins- SAN DIEGO, Jan. 12, 2023 (GLOBE.

Joyce allaireLinda marbanRaquel conaLifesci advisorsExchange commission onStrategic communicationsCapricor therapeutics incCapricor company contactPrivate securities litigation reform actAnnual reportExchange commissionQuarterly reportInvestigational new drugMedia contactInvestor contactSci advisors

vimarsana © 2020. All Rights Reserved.